Clinical Trial Update: Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis [NA]

View source ↗

Summary

A clinical trial evaluating oral budesonide for primary biliary cirrhosis with overlap features of autoimmune hepatitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hepatitis
• Biliary Cirrhosis

Drugs mentioned

• Budesonide (BUDESONIDE)

Snippet

Sponsor: Mayo Clinic | Conditions: Primary Biliary Cirrhosis, Autoimmune Hepatitis | NA | Status: WITHDRAWN